Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome
Authors:
Open Access
- 1 September 2007
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 14 (3) , 799-807
Abstract
Bone is the second most frequent target of distant metastases in patients with differentiated thyroid cancer, and such forms carry a very poor prognosis. The impact of 131I therapy in this setting is controversial. We describe the diagnostic circumstances and outcome of patients with bone metastases recently managed in two institutions. Among 921 consecutive thyroid cancer patients who had total thyroidectomy and 131I ablation between January 2000 and December 2004 and who were subsequently monitored, bone metastases had been diagnosed in 16 patients. In three cases, the bone metastases were non-functioning (negative 131I uptake) . These patients were treated with surgery and radiotherapy but progressed rapidly. The other 13 patients had functioning (positive 131I uptake) bone metastases. In five of them, thyroid cancer was revealed by signs of distant involvement (bone pain, n = 4; dyspnea, n = 1). The bone metastases progressed in these five patients, despite local therapy and multiple courses of 131I. The bone metastases in the remaining eight patients were discovered on the post-surgery 131I therapy scan. Complementary radiological studies were negative except in one patient in whom one of the metastases (a 5 mm lesion of the right humerus) was visible on magnetic resonance imaging (MRI). Six of these patients showed a good response to 131I therapy, with 131I uptake and Tg levels becoming undetectable or showing a sharp fall. One patient refused 131I therapy; bone metastases became visible on MRI within 1 year and the Tg level rose tenfold. The disease progressed in one patient despite 131I therapy. Post-surgical 131I ablation can contribute to early detection of bone metastases at a time when the Tg level may be only moderately elevated, when other radiological studies are negative, and when the disease is potentially curable by 131I therapy.Keywords
This publication has 20 references indexed in Scilit:
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- Single-Photon Emission Computed Tomography/Computed Tomography in EndocrinologySeminars in Nuclear Medicine, 2006
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Survival and Therapeutic Modalities in Patients with Bone Metastases of Differentiated Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2001
- Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of ageEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodineWorld Journal of Surgery, 1994
- Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?World Journal of Surgery, 1992
- Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroidCA: A Cancer Journal for Clinicians, 1990
- Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*The Journal of Clinical Endocrinology & Metabolism, 1988
- Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experienceBritish Journal of Radiology, 1984